<DOC>
	<DOC>NCT01426854</DOC>
	<brief_summary>The purpose of this study was to demonstrate that Nepafenac Ophthalmic Suspension, 0.1% is superior to Nepafenac Vehicle (placebo) for the prevention and treatment of ocular inflammation and pain associated with cataract surgery in Chinese subjects.</brief_summary>
	<brief_title>Nepafenac Compared to Placebo for Ocular Pain and Inflammation</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Adult Chinese subjects, 18 years of age or older, of either sex who have a cataract, and are expected to undergo cataract extraction with the implantation of a posterior chamber intraocular lens; Study eye of subjects, who in the opinion of the Investigator, will have improvement in bestcorrected visual acuity after surgery; Subjects should be able to understand and sign an informed consent that has been approved by an Independent Ethics Committee; Other protocoldefined inclusion criteria may apply. Use of topical ocular or systemic steroids within 14 days prior to surgery; Use of topical ocular or systemic nonsteroidal antiinflammatory drugs within 7 days of surgery, except an allowed daily dose of baby aspirin (81 mg); Subjects planning to have cataract surgery in their fellow, nonstudy eye prior to the 14 day postoperative study visit; Any intraocular inflammation or ocular pain greater than Grade 0 in the study eye that is present during the baseline slitlamp exam; Women of childbearing potential (those who are not surgically sterilized or post menopausal) may not participate in the study if any of the following conditions exist: they are breast feeding; they have a positive urine pregnancy test at baseline; they are not willing to undergo a urine pregnancy test upon exiting the study; they intend to become pregnant during the duration of the study; or, they do not agree to using adequate birth control methods for the duration of the study. Any abnormality that prevents reliable tonometry; Planned multiple procedures during cataract/IOL implantation surgery; Lens pseudoexfoliation syndrome with glaucoma or zonular compromise; Previous ocular trauma to the operative eye; A history of chronic or recurrent inflammatory eye disease; Ocular infection or ocular pain; Proliferative diabetic retinopathy; Uncontrolled diabetes mellitus; Congenital ocular anomaly; Iris atrophy in the operative eye; A nonfunctional fellow eye; Use of an investigational intraocular lens; Participation in any other clinical study within 30 days before surgery; Known or suspected allergy or hypersensitivity to nonsteroidal antiinflammatory agents, or to any component of the study medication; Subjects with known bleeding tendencies, or who are receiving medications that may prolong bleeding time, may be enrolled at the physician's discretion; continuation of previous therapy for these subjects will be left to the judgment of the physician; The fellow eye of an individual currently or previously enrolled in the study; Subjects using a topical ophthalmic prostaglandin; Subjects, who in the opinion of the investigator, might be at increased risk of complications from topical NSAIDs; Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Cataract Surgery</keyword>
	<keyword>Anti-ocular Inflammation</keyword>
	<keyword>Anti-ocular Pain</keyword>
</DOC>